Evidence map›Paper›PMID 34199192›Full record

ArticleMolecules (Basel, Switzerland)2021

Targeting Melanoma-Initiating Cells by Caffeine: In Silico and In Vitro Approaches.

Claudio Tabolacci, Martina Cordella, Stefania Rossi, Marialaura Bonaccio, Adriana Eramo, Carlo Mischiati, Simone Beninati, Licia Iacoviello, Antonio Facchiano, Francesco Facchiano

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Life Factors and Melanoma: From the Macroscopic State to the Molecular Mechanism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Phytochemicals as Immunomodulatory Agents in Melanoma.International journal of molecular sciences · 2023
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Claudio TabolacciDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.ORCID 0000-0001-5001-285X
Martina CordellaDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Stefania RossiDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.ORCID 0000-0002-8854-7072
Marialaura BonaccioDepartment of Epidemiology and Prevention, IRCCS Neuromed, 86077 Pozzilli, Italy.ORCID 0000-0002-8082-6552
Adriana EramoDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Carlo MischiatiDepartment of Neuroscience and Rehabilitation, School of Medicine, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-0029-2205
Simone BeninatiDepartment of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-2704-0745
Licia IacovielloDepartment of Epidemiology and Prevention, IRCCS Neuromed, 86077 Pozzilli, Italy.ORCID 0000-0003-0514-5885
Antonio FacchianoLaboratory of Molecular Oncology, IDI-IRCCS, 00167 Rome, Italy.ORCID 0000-0002-4243-2392
Francesco FacchianoDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Istituto Superiore di Sanità · ITIstituto Dermopatico dell'Immacolata · ITIstituto Neurologico Mediterraneo · ITUniversity of Ferrara · ITUniversity of Insubria · ITUniversity of Rome Tor Vergata · IT

Funding

Banca d'Italia Contributo LiberaleMinistero della Salute Italy-USA Oncoproteomic ProgramMinistero della Salute Oncotechnology ProgramMinistero della Salute RC 2020-3.4
6 · The paper itself

Abstract

The beneficial effects of coffee on human diseases are well documented, but the molecular mechanisms of its bioactive compounds on cancer are not completely elucidated. This is likely due to the large heterogeneity of coffee preparations and different coffee-based beverages, but also to the choice of experimental models where proliferation, differentiation and immune responses are differently affected. The aim of the present study was to investigate the effects of one of the most interesting bioactive compounds in coffee, i.e., caffeine, using a cellular model of melanoma at a defined differentiation level. A preliminary in silico analysis carried out on public gene-expression databases identified genes potentially involved in caffeine's effects and suggested some specific molecular targets, including tyrosinase. Proliferation was investigated in vitro on human melanoma initiating cells (MICs) and cytokine expression was measured in conditioned media. Tyrosinase was revealed as a key player in caffeine's mechanisms of action, suggesting a crucial role in immunomodulation through the reduction in IL-1β, IP-10, MIP-1α, MIP-1β and RANTES secretion onto MICs conditioned media. The potent antiproliferative effects of caffeine on MICs are likely to occur by promoting melanin production and reducing inflammatory signals' secretion. These data suggest tyrosinase as a key player mediating the effects of caffeine on melanoma.

Indexed as

CaffeineCell DifferentiationCell Line, TumorCentral Nervous System StimulantsComputational BiologyComputer SimulationDatabases, GeneticGene Expression RegulationHumansMelaninsMelanomaMonophenol MonooxygenaseCaffeineCentral Nervous System StimulantsMelaninsMonophenol Monooxygenasebioactive compoundscaffeineimmunomodulatory signalsmelaninmelanoma

Identifiers

PMID34199192
PMCPMC8231844
OpenAlexW3166765963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.